BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

17 related articles for article (PubMed ID: 16442918)

  • 1. Coping effectively with heart failure (COPE-HF): design and rationale of a telephone-based coping skills intervention.
    Sherwood A; O'Connor CM; Routledge FS; Hinderliter AL; Watkins LL; Babyak MA; Koch GG; Adams KF; Dupree CS; Chang PP; Hoffman BM; Johnson J; Bowers M; Johnson KS; Blumenthal JA
    J Card Fail; 2011 Mar; 17(3):201-7. PubMed ID: 21362527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC; Stough WG; Abraham WT; Albert NM; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Am Coll Cardiol; 2007 Aug; 50(8):768-77. PubMed ID: 17707182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    O'Connor CM; Abraham WT; Albert NM; Clare R; Gattis Stough W; Gheorghiade M; Greenberg BH; Yancy CW; Young JB; Fonarow GC
    Am Heart J; 2008 Oct; 156(4):662-73. PubMed ID: 18926148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of heart rate recovery in patients with heart failure or left ventricular systolic dysfunction.
    Lipinski MJ; Vetrovec GW; Gorelik D; Froelicher VF
    J Card Fail; 2005 Oct; 11(8):624-30. PubMed ID: 16230267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
    Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF.
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Card Fail; 2007 Nov; 13(9):722-31. PubMed ID: 17996820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality benefit of a comprehensive heart failure disease management program in indigent patients.
    Hebert KA; Horswell RL; Dy S; Key IJ; Butler MK; Cerise FP; Arcement LM
    Am Heart J; 2006 Feb; 151(2):478-83. PubMed ID: 16442918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conceptual model for heart failure disease management.
    Andrikopoulou E; Abbate K; Whellan DJ
    Can J Cardiol; 2014 Mar; 30(3):304-11. PubMed ID: 24565255
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.